Price Alert

KalVista Pharmaceuticals ... (KALV)

NASDAQ: KALV · Real-Time Price · USD

12.40

0.30 (2.52%)

At close: Sep 26, 2025, 3:59 PM

12.30

-0.81%

After-hours: Sep 26, 2025, 05:30 PM EDT

2.52% (1D)

Bid	11.65
Market Cap	626.49M
Revenue (ttm)	1.43M
Net Income (ttm)	-203.1M
EPS (ttm)	-3.94
PE Ratio (ttm)	-3.15
Forward PE	-3.92
Analyst	Buy
Dividends	n/a

Ask	12.95
Volume	2,001,801
Avg. Volume (20D)	1,367,620
Open	12.19
Previous Close	12.10
Day's Range	11.99 - 12.47
52-Week Range	7.30 - 17.28
Beta	-0.10
Ex-Dividend Date	n/a

About KALV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KALV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KALV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

KalVista Pharmaceuticals Inc. is scheduled to release its earnings on Dec 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 days ago New

-6.42%

KalVista shares are trading lower after the compan... Unlock content with Pro Subscription

2 days ago

-0.69%

KalVista Pharmaceuticals shares are trading lower after the company announced a $110 million private offering.

News

1 day ago · businesswire.com

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Aller...

2 days ago · businesswire.com

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate principal a...

3 days ago · businesswire.com

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other fac...

1 week ago · businesswire.com

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swis...

2 weeks ago · seekingalpha.com

KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Q1 2026 Earnings Call September 11, 2025 8:30 AM EDT Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Nicol...

2 weeks ago · zacks.com

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.87 per share a year ago.

2 weeks ago · businesswire.com

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal quarter ended...

2 weeks ago · benzinga.com

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

KalVista Pharmaceuticals, Inc. KALV will release earnings results for the first quarter before the opening bell on Thursday, Sept. 11.

3 weeks ago · businesswire.com

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted two newl...

1 month ago · businesswire.com

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines ...

Load More News